Claims for Patent: 8,258,118

Summary for Patent: 8,258,118

Title:	4-pyridinone compounds and their use for cancer
Abstract:	Disclosed are compounds of Formula (I): ##STR00001## and salts thereof. Also, disclosed are methods of using the compounds in the treatment of proliferative diseases, such as cancer, and to pharmaceutical compositions comprising at least one compound of Formula (I) or a pharmaceutically acceptable salt.
Inventor(s):	Borzilleri; Robert M. (New Hope, PA), Cai; Zhen-Wei (Belle Mead, NJ)
Assignee:	Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:	13/349,173
Patent Claims:	1. A method for treating cancer in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of a compound having the following Formula (I): ##STR00043## wherein: G is H, --CHX--OP(.dbd.O)(OH).sub.2, or --CHX--OC(.dbd.O)Z; X is H or alkyl optionally substituted with one or more of OH, halogen, cyano, and/or --NR.sup.1R.sup.2; Z is alkyl, cycloalkyl, aryl, or heterocyclo optionally substituted with one or more of alkyl, OH, halogen, cyano, and/or --NR.sup.3R.sup.4; and R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently H and/or alkyl; or a pharmaceutically salt thereof. 2. The method according to claim 1 wherein said cancer is bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreas/gall bladder cancer, prostate cancer, thyroid cancer, osteosarcoma, rhabdomyosarcoma, melanoma, glioblastomas/astrocytomas, MFH/fibrosarcoma, or mesothelioma. 3. The method according to claim 1 wherein said compound is: ##STR00044## or a pharmaceutically salt thereof. 4. The method according to claim 1 wherein said patient is human. 5. The method according to claim 1, further comprising administering an additional anticancer agent. 6. The method according to claim 5 wherein said additional anticancer agent is gefitinib, erlotinib, or cetuximab. 7. The method according to claim 1 wherein said cancer is dependent upon Met activation, wherein the Met activation is regulated by gene amplification, and activated Met mutation, and/or HGF stimulation. 8. The method according to claim 3 wherein said compound is: ##STR00045## or a pharmaceutically acceptable salt thereof. 9. The method according to claim 8 wherein said compound is: ##STR00046## 10. The method according to claim 8 wherein said compound or pharmaceutically acceptable salt thereof is a bis-trisamine salt. 11. The method according to claim 3 wherein said compound is: ##STR00047## 12. The method according to claim 2 wherein said cancer is bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, melanoma, ovarian cancer, pancreas/gall bladder cancer, prostate cancer, or thyroid cancer. 13. The method according to claim 12 wherein said cancer is bladder cancer, gastric cancer, head and neck cancer, or lung cancer. 14. The method according to claim 12 wherein said cancer is prostate cancer. 15. The method according to claim 12 wherein said cancer is breast cancer. 16. The method according to claim 12 wherein said cancer is kidney cancer. 17. The method according to claim 12 wherein said cancer is melanoma. 18. The method according to claim 12 wherein said cancer is colorectal cancer. 19. The method according to claim 12 wherein said cancer is gastric cancer. 20. The method according to claim 12 wherein said cancer is ovarian cancer.

Details for Patent 8,258,118

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2028-01-23
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2028-01-23